tiprankstipranks
Advertisement
Advertisement
Maintained Buy Rating on Viking Therapeutics Reflects Confidence in Pipeline Strength and Favorable Risk‑Reward Profile
PremiumRatingsMaintained Buy Rating on Viking Therapeutics Reflects Confidence in Pipeline Strength and Favorable Risk‑Reward Profile
2M ago
Viking Therapeutics rises 10.7%
Premium
The Fly
Viking Therapeutics rises 10.7%
2M ago
Unusually active option classes on open February 23rd
Premium
The Fly
Unusually active option classes on open February 23rd
2M ago
Viking Therapeutics options imply 9.5% move in share price post-earnings
PremiumThe FlyViking Therapeutics options imply 9.5% move in share price post-earnings
2M ago
VKTX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
VKTX Earnings this Week: How Will it Perform?
2M ago
Viking Therapeutics management to meet virtually with Oppenheimer
Premium
The Fly
Viking Therapeutics management to meet virtually with Oppenheimer
3M ago
Positioning Viking Therapeutics’ VK2735 as a Differentiated, Best-in-Class Obesity Franchise with Compelling Monthly Maintenance Potential Supporting a Buy Rating
PremiumRatingsPositioning Viking Therapeutics’ VK2735 as a Differentiated, Best-in-Class Obesity Franchise with Compelling Monthly Maintenance Potential Supporting a Buy Rating
3M ago
Viking Therapeutics completes enrollment in trial of VK2735
Premium
The Fly
Viking Therapeutics completes enrollment in trial of VK2735
3M ago
Viking Therapeutics names Neil Aubuchon as Chief Commercial Officer
Premium
The Fly
Viking Therapeutics names Neil Aubuchon as Chief Commercial Officer
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100